

# Sharp Therapeutics Corp.

Amendment to Management Certification for 12/31/2024 originally published through the OTC Disclosure & News Service on [08/07/2025](#)

## Explanatory Note:

Original was missing the date signed - no other changes made.

*\*\*This coversheet was automatically generated by OTC Markets Group based on the information provided by the Company. OTC Markets Group has not reviewed the contents of this amendment and disclaims all responsibility for the information contained herein.*

The undersigned, on behalf of Sharp Therapeutics Corp. ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

**SEC Reporting Obligations**

- The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- The Company has a reporting obligation under Regulation A (Tier 2)
- The Company has a reporting obligation under Regulation Crowdfunding (CF)
- Other (please describe)

**Other Reporting Obligations**

- The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard

2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes  No

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes  No

4. The Company has a Verified Company Profile on OTCMarkets.com.

5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.

6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.

7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.

8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.

Transfer Agent: TSX Trust Company  
Address: 300-100 Adelaide St. W., Toronto ON

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

MNP LLP, Chartered Accountants  
1 Adelaide St. E., Toronto, ON M5C 2V9

10. The Company's Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3,4, and 5.

As of (latest practicable date): June 30, 2025

Individual Name (First, Last) or Entity Name (include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% beneficial owner)	City and State (Include Country if outside USA)	Number of Shares Owned (list common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Scott Sneddon*	CEO & Director	Pittsburgh, PA	870,247 927,295	Common Options	2.9% 62.07%
Edward Jonasson	CFO	Toronto, ON Canada	30,000 12,452	Common Options	0.1% 0.83%
William R. Newlin*	Director	Naples, FL	4,881,842	Common	16.3%
John L. Brooks III	Director	Medfield, MA			
Dietrich Stephan	Director	Pittsburgh, PA	16,084	Options	10.77%
John Hathaway*	Director	Pittsburgh, PA	9,019,506	Common	30.1%
Lorne Sugarman	Director	Toronto, ON Canada	60,000 18,250	Common Options	0.2% 1.22%

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

\*Directors Scott, William and John also hold shares in a 5D Value Escrow Agreement shown on the register as *EFTC ESCROW SHARE NOMINEE - 5D VALUE*.

The 5D Value shares for William R. Newlin are both in his personal name and his entity Newlin Investment Company, LLC.

The 5D Value shares for John Hathaway are both in his personal name and his entity STX Partners LLC.

The balance of the 5D Value shares are registered to individuals, each totaling under 5%.

The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (Include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion	Name of Noteholder (entities must have individual with voting/investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below:

**Signature:**

Name of Principal Executive Officer or Principal Financial Officer: Edward Jonasson

Title: CFO

Date: **August 6, 2025**

Signature: /s/ Edward Jonasson

(Digital Signatures should appear as "/s/ [OFFICER NAME]")